Currently, the following molecules are known to inhibit TGF-β/Smad signaling: 1) miR-106 targeting Smad7 inhibits gastric CSCs and is implicated as a potential biomarker in CRC, and 2) Dkk-3 inhibits matrix metallopeptidases 9/13, which are downstream TGF-β-induced enzymes, implicated in preventing prostate CSC metastasis (Peng et al., 2020; Yang et al., 2020). This evidence concerns the gene TGFB1 and colorectal carcinoma.